Zamberlan, N <br/><br/>
Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  1997 
 - 133-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0937-941X 
<br/><br/><label>Standard No.: </label>10.1007/BF01623688  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anthropometry<br/>Bone Density--drug effects<br/>Calcium--therapeutic use<br/>Drug Therapy, Combination<br/>Etidronic Acid--therapeutic use<br/>Female<br/>Hirsutism--drug therapy<br/>Humans<br/>Luteolytic Agents--adverse effects<br/>Osteoporosis--chemically induced<br/>Polycystic Ovary Syndrome--drug therapy<br/>Triptorelin Pamoate--adverse effects